Objective: To systematically evaluate the diagnostic value of 3.0T MR Dynamic enhancement in prostate cancer among fitness and athletic patients, aiming to offer insights for the selection of early diagnostic techniques in this specific population. Methods: This study conducted a comprehensive search in Cochrane Library, Web of Science, PubMed, Proquest, and Chinese biomedical literature databases including Wanfang, Wipu, and CNKI, focusing on literature published until September 2022. The search was tailored to assess the value of 3.0T MR dynamic enhancement in diagnosing prostate cancer in fitness and athletic individuals. A meta-analysis was performed on the selected studies to calculate combined sensitivity, specificity, positive and negative likelihood ratios, and diagnostic odds ratio. Sensitivity-specific forest plots, SROC curves, and funnel plots were employed to evaluate publication bias. Results: The metaanalysis included seven studies, comprising a total of 516 subjects who were actively involved in fitness or athletic activities. Among these, 216 were true positive cases, 204 true negative, 43 false positive, and 53 false negative. The analysis revealed that the combined sensitivity of 3.0T MR Dynamic enhancement for prostate cancer diagnosis in this population was 0.82 (95% CI: 0.73, 0.90), and the combined specificity was 0.83 (95% CI: 0.77, 0.88). The combined positive likelihood ratio was 4.91 (95% CI: 3.25, 7.16), and the negative likelihood ratio was 0.21 (95% CI: 0.12, 0.26). The diagnostic odds ratio was 35.28 (95% CI: 16.57, 40.32), with an AUC of 0.86 (95% CI: 0.81, 0.92). No significant heterogeneity due to non-threshold effects (p>0.01) was observed, and a fixed effect model was applied. No publication bias was detected (P>0.05). Conclusion: 3.0T MR Dynamic enhancement demonstrates high sensitivity and specificity in the diagnosis of prostate cancer among fitness and athletic patients, indicating its significant diagnostic value in this specific demographic.